Safety and Effectiveness of Giving SU5416 to HIV-Infected Patients With AIDS-Related Kaposi's Sarcoma
The purpose of this study is to see if it is safe and effective to give SU5416 to HIV-infected patients with AIDS-related Kaposi's sarcoma (KS). SU5416 may prevent the growth of KS tumors.
|Study Design:||Endpoint Classification: Safety Study
Primary Purpose: Treatment
|Official Title:||A Multicenter, Dose Escalating Study in Patients With Cutaneous AIDS-Related Kaposi's Sarcoma|
Groups of 3-6 patients are sequentially assigned to receive escalating doses of SU5416 in 33% increments. Study drug is administered as a twice-weekly intravenous injection for 4 weeks. In the absence of unacceptable toxicity, responding patients may continue on SU5416 in 4-week treatment cycles for a maximum of 1 year or until the presence of unacceptable toxicity or tumor progression.
|United States, California|
|UCLA Care Ctr / Ctr for Hlth Sciences|
|Los Angeles, California, United States, 900951793|
|Norris Cancer Ctr / USC|
|Los Angeles, California, United States, 90033|
|Saint Francis Mem Hosp / HIV Care Unit|
|San Francisco, California, United States, 94109|
|United States, New York|
|New York Univ Med Ctr|
|New York, New York, United States, 10016|